Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 3 de 3
1.
Endocr J ; 67(4): 449-454, 2020 Apr 28.
Article En | MEDLINE | ID: mdl-31956210

The tissue-specific circulating markers of thyroid hormone action on cardiac function have not been established. Although the relationship between thyroid function and plasma brain natriuretic peptide (BNP) levels has been evaluated in patients with thyroid disorders, the relationship between these parameters in the general population has not been yet studied. We conducted retrospective cohort study by health examination with concurrent measurements of TSH, free T4, body mass index, systolic blood pressure, hemoglobin, and estimated glomerular filtration rate from participants who visited the Department of Health Checkup, Enshu Hospital between July 2008 and March 2017. After participants with abnormal electrocardiogram and/or any history of cardiac disease were excluded, 2,807 individuals were subjected. Multivariate analyses demonstrated that, when compared to euthyroidism (n = 2,629), the increase in BNP levels was significant in overt thyrotoxicosis (n = 21) but not in subclinical thyrotoxicosis (n = 53) or subclinical hypothyroidism (n = 97). Interestingly, the standardized partial regression coefficient was the smallest for thyroid function category (overt thyrotoxicosis compared to euthyroidisim; ß = 0.048, p = 0.006) among the independent variables including age, body mass index, systolic blood pressure, and hemoglobin. In longitudinal comparison, we identified 986 participants who had sequential data on the measurements and were stable as euthyroidism and subclinical hypothyroidism. Their annual percent change in BNP demonstrated no significant differences. In conclusion, a direct stimulatory effect of thyroid hormone on the secretion (or production) of BNP was confirmed even in a large number of health examination participants.


Hypothyroidism/blood , Natriuretic Peptide, Brain/blood , Thyrotoxicosis/blood , Thyrotropin/blood , Thyroxine/blood , Adult , Aged , Asymptomatic Diseases , Blood Pressure , Body Mass Index , Female , Glomerular Filtration Rate , Hemoglobins/metabolism , Humans , Male , Middle Aged , Multivariate Analysis , Retrospective Studies
2.
J Mol Endocrinol ; 45(3): 133-45, 2010 Sep.
Article En | MEDLINE | ID: mdl-20587609

Peroxisome proliferator-activated receptor gamma-2 (PPARG2) is a ligand-dependent transcriptional factor involved in the pathogenesis of insulin resistance. In the presence of a ligand, PPARG2 associates with co-activators, while it recruits co-repressors (CoRs) in the absence of a ligand. It has been reported that the interaction of liganded PPARG2 with co-activators is regulated by the amino-terminal A/B domain (NTD) via inter-domain communication. However, the role of the NTD is unknown in the case of the interaction between unliganded PPARG2 and CoRs. To elucidate this, total elimination of the influence of ligands is required, but the endogenous ligands of PPARG2 have not been fully defined. PPARG1-P467L, a naturally occurring mutant of PPARG1, was identified in a patient with severe insulin resistance. Reflecting its very low affinity for various ligands, this mutant does not have transcriptional activity in the PPAR response element, but exhibits dominant negative effects (DNEs) on liganded wild-type PPARG2-mediated transactivation. Using the corresponding PPARG2 mutant, PPARG2-P495L, we evaluated the role of the NTD in the interaction between unliganded PPARG2 and CoRs. Interestingly, the DNE of PPARG2-P495L was increased by the truncation of its NTD. NTD deletion also enhanced the DNE of a chimeric receptor, PT, in which the ligand-binding domain of PPARG2 was replaced with that of thyroid hormone receptor beta-1. Moreover, NTD deletion facilitated the in vitro binding of nuclear receptor CoR with wild-type PPARG2, mutant P495L, and the PT chimera (PPARG2-THRB). Inter-domain communication in PPARG2 regulates not only ligand-dependent transactivation but also ligand-independent silencing.


Co-Repressor Proteins/metabolism , PPAR gamma/chemistry , PPAR gamma/metabolism , Animals , Cell Line , Genes, Dominant , Humans , Ligands , Mice , Mutant Proteins/metabolism , Protein Binding , Protein Structure, Tertiary , Recombinant Proteins/metabolism , Sequence Deletion/genetics , Structure-Activity Relationship , Thyroid Hormone Receptors beta/genetics , Thyroid Hormone Receptors beta/metabolism
3.
Endocrinology ; 145(12): 5515-24, 2004 Dec.
Article En | MEDLINE | ID: mdl-15319359

The thyroid hormone receptor (TR) and liver X receptor (LXR)-alpha are members of the nuclear hormone receptor family and are ligand-dependent transcription factors. Among the promoter target genes, TR and LXR recognize the T3 response element and LXR response element (LXRE), respectively. Because T3 response elements and LXREs have similar configurations, referred to as direct repeat 4, we investigated the possibility of cross-talk between the two ligand-dependent signal transduction pathways. We found that TRbeta1, a major isoform of TR in the liver, binds and transactivates LXREs derived from the mouse mammary tumor virus long-terminal repeat and the promoter of the sterol regulatory element binding protein 1c. Moreover, unliganded TRbeta1 suppresses promoter activity driven by LXRalpha and its ligand, whereas transactivation by T3-bound TRbeta1 is not affected by LXRalpha in the presence or absence of oxysterols. Gel shift, mammalian two-hybrid, and glutathione S-transferase pull-down assays demonstrated the direct binding of TRbeta1 to these LXREs and revealed that the interaction between TRbeta1 and corepressors is important to the unliganded TR-mediated suppression of LXRalpha-transactivation. Our findings suggest that T3 and TR influence lipid metabolism regulated by oxysterol/LXRalpha at the transcriptional level.


Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Signal Transduction/physiology , Thyroid Hormone Receptors beta/genetics , Thyroid Hormone Receptors beta/metabolism , Animals , CCAAT-Enhancer-Binding Proteins/genetics , Carcinoma, Hepatocellular , Cell Line, Tumor , DNA-Binding Proteins/genetics , Dimerization , Gene Expression/drug effects , Gene Expression/physiology , Humans , Kidney/cytology , Ligands , Lipid Metabolism , Liver Neoplasms , Liver X Receptors , Mutagenesis , Orphan Nuclear Receptors , Promoter Regions, Genetic/physiology , Receptor Cross-Talk/physiology , Receptors, Cytoplasmic and Nuclear/chemistry , Sterol Regulatory Element Binding Protein 1 , Thyroid Hormone Receptors beta/chemistry , Transcription Factors/genetics , Transcription, Genetic/drug effects , Transcription, Genetic/physiology , Triiodothyronine/pharmacology
...